Physician profile
Robert P Forrest
NPI 1588696082
$2,216.08
in general payments reported to CMS, 2019-2025
18 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.08 · 2021: $201 · 2022: $634 · 2023: $739 · 2024: $283 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.81 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $253.27 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $220.61 | 2020-2025 | Aristada, Lybalvi |
| Corium, LLC | $198.86 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $188.56 | 2021-2023 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $129.67 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $127.61 | 2021-2025 | Trintellix |
| Lundbeck LLC | $124.21 | 2021-2025 | Rexulti |
| Tris Pharma INC | $95.53 | 2020-2023 | Dyanavel Xr |
| Bausch Health US, LLC | $41.72 | 2022 | |
| Axsome Therapeutics, INC. | $40.00 | 2023 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $32.45 | 2022-2024 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $27.55 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.61 | 2023 | |
| Ironshore Pharmaceuticals INC. | $17.98 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $14.22 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.32 | 2022 | |
| Allergan, INC. | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Forrest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.